Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice

Abstract

In the legends of both Conditions were the same as those given in Fig. 2, except the dose of Cy used was 150 mg/kg. Mice were sacrificed on day 128 and thymocyte suspensions prepared. R mice rechallenged on day 60 by i.p. implantation of 5x 104 viable EL4 tumor cells: VR mice not rechallenged. Evaluation of cytolytic activity after stimulation culture was against both EL4 or C1498 radiolabeled tumor target cells and in both 6-h and 18-h 51 Cr-release assays. R thymocytes were also examined for cytolytic activity on day 128. Immediately after the thymus had been obtained from the mice and single-cell suspensions prepared. These fresh R thymocytes (F-R) were plated with IL-2 (2.4 ng/ml) and radiolabeled target cells and 51 Cr release was assessed 18 h later

In Vitro Cytotoxicity of Recombinant Human-TNF-.ALPHA. and Actinomycin D on Canine Normal and Tumor Cells.

“…TNF has been known to show marked anticancer effects on certain transplantable tumors [4]. The potential mechanisms of TNF are the vascular changes in tumor tissues [22,30], the modulation of host immunity against tumors [13,24] and the direct cytotoxicity on tumor cells by inducing apoptosis [5,29].…”